Source comparison
Best Peptides for Ligament Repair: Research Comparison
BPC-157 VEGF upregulation, growth hormone receptor modulation, nitric oxide pathway activation 2.3–4.5 mg/day subcutaneous (14–28 days) 72% increase in ligament-to-bone healing strength vs controls (J Orthop Res, 2019) Limited human clinical trials; most data
This comparison does not assign a generated winner or score.
- BPC-157
- VEGF upregulation, growth hormone receptor modulation, nitric oxide pathway activation
- 2.3–4.5 mg/day subcutaneous (14–28 days)
- 72% increase in ligament-to-bone healing strength vs controls (J Orthop Res, 2019)
- Limited human clinical trials; most data from rodent models; half-life requires twice-daily dosing
- Most robust preclinical evidence for direct ligament repair; works via multiple complementary pathways
- TB-500
- Actin binding, cell migration enhancement, inflammatory cytokine downregulation
- 0.8–3.2 mg twice weekly subcutaneous (4–6 weeks)
- 55% reduction in scar tissue formation in cardiac injury models (Am J Physiol)
- Longer treatment duration required; effects plateau after 6 weeks; limited ligament-specific research
- Best for preventing excessive scar tissue; combines well with BPC-157 for synergistic effects
- GHK-Cu
- Matrix metalloproteinase activation, TGF-β stimulation, collagen cross-linking via lysyl oxidase
- 1–3 mg/day subcutaneous
- 70% increase in collagen content with improved organisation (Wound Repair Regen)
- Rapid oxidation once reconstituted; light-sensitive; copper component requires careful storage
- Strongest evidence for collagen remodelling quality; essential for long-term tensile strength recovery